Peripheral T-cell lymphomas (PTCL) are uncommon types of non-Hodgkin lymphoma (NHL) which develop in T-cells and NK-cells and are often aggressive, with outcomes for patients being generally poor. There is a great medical need to further our understanding of the biology and pathology of these tumors in order to contribute towards the development of novel treatment approaches and improve patient outcomes.
This article collection will be dedicated to publishing research which advances our understanding of the biological aspects of PTCL, PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and related diseases, ALK -positive and -negative anaplastic large cell lymphoma (ALCL), and extra-nodal NK/T-cell lymphoma (ENKTCL-NT). We will collate the latest evidence on diagnostic approaches and classifications, biology, pathophysiology, clinical and laboratory prognostic factors, and molecular biomarkers in this group of complex and heterogeneous diseases. Therapeutic advances in the field will also be addressed, including first-line treatment, therapy of relapsed/refractory disease, “classic” and “new” therapeutic strategies, and the role of autologous hematopoietic stem cell transplant.
We welcome the submission of Original Research, Review, Systematic Review or Mini-Review type articles.
The Topic Coordinator of this collection is Dr. Luís Alberto de Pádua Covas Lage, MD, PhD, affiliated to University of São Paulo. His expertise is in biological aspects and molecular biomarkers, with a focus on the diagnosis and prognosis of PTCL.
Important note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Peripheral T-cell lymphomas (PTCL) are uncommon types of non-Hodgkin lymphoma (NHL) which develop in T-cells and NK-cells and are often aggressive, with outcomes for patients being generally poor. There is a great medical need to further our understanding of the biology and pathology of these tumors in order to contribute towards the development of novel treatment approaches and improve patient outcomes.
This article collection will be dedicated to publishing research which advances our understanding of the biological aspects of PTCL, PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and related diseases, ALK -positive and -negative anaplastic large cell lymphoma (ALCL), and extra-nodal NK/T-cell lymphoma (ENKTCL-NT). We will collate the latest evidence on diagnostic approaches and classifications, biology, pathophysiology, clinical and laboratory prognostic factors, and molecular biomarkers in this group of complex and heterogeneous diseases. Therapeutic advances in the field will also be addressed, including first-line treatment, therapy of relapsed/refractory disease, “classic” and “new” therapeutic strategies, and the role of autologous hematopoietic stem cell transplant.
We welcome the submission of Original Research, Review, Systematic Review or Mini-Review type articles.
The Topic Coordinator of this collection is Dr. Luís Alberto de Pádua Covas Lage, MD, PhD, affiliated to University of São Paulo. His expertise is in biological aspects and molecular biomarkers, with a focus on the diagnosis and prognosis of PTCL.
Important note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
